Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.45M

Average 2.00M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$125.25M

FY 2025 · Annual

Investing Cash Flow

$131.62M

FY 2025 · Annual

-25.5% YoY

Financing Cash Flow

-$4.28M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(166.09M)(237.11M)(292.19M)(165.87M)(137.06M)
Depreciation & Amortization544K1.43M1.39M1.29M739K
Deferred Income Tax(2.51M)(769K)(853K)00
Stock-Based Compensation35.74M46.84M54.82M67.27M20.72M
Change in Working Capital16.61M13.25M5.86M(16.54M)(9.12M)
Accounts Receivables413K00(5M)5M
Inventory00000
Accounts Payables13.96M15.53M10.92M(18.02M)(17.32M)
Other Working Capital2.23M(2.28M)(5.06M)6.48M3.19M
Other Non-Cash Items(38.38M)12.61M23.15M(57.01M)(526K)
Operating Cash Flow(154.09M)(163.75M)(207.82M)(170.86M)(125.25M)
Capital Expenditures(6.11M)(2.55M)(583K)(221K)0
Acquisitions (Net)(14.32M)111.63K065K0
Purchases of Investments(363.51M)(533.16M)(549.18M)(127.96M)(139.49M)
Sales of Investments365.82M421.53M505.31M304.68M270.41M
Other Investing Activities0(111.63K)00698K
Investing Cash Flow(18.12M)(114.18M)(44.46M)176.56M131.62M
Debt Repayment00000
Common Stock Issued179.67M261.04M237.3M349K(4.28M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.15M)00(241K)0
Financing Cash Flow178.52M261.04M237.3M108K(4.28M)
Effect of Forex Changes00000
Net Change in Cash6.31M(16.89M)(14.98M)5.81M2.09M
Free Cash Flow(160.2M)(166.3M)(208.41M)(171.08M)(125.25M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$137.1M
+ D&A$739.0K
+ Stock-Based Comp$20.7M
+ Deferred Tax$0
- Working Capital-$9.1M
- Other Non-Cash-$526.0K
= Operating Cash Flow-$125.2M
- Capex$0
= Free Cash Flow-$125.2M

Analysis

FY2025 free cash flow is -$125.2M. FCF conversion is 91.4% of net income. Operating cash flow was -$125.2M, with capex of $0. The largest bridge item is Stock-Based Comp at $20.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 1, 2026
4Statement of changes in beneficial ownershipAug 19, 2026

Does ZNTL generate free cash flow?

Zentalis Pharmaceuticals, Inc. (ZNTL) generated -$125.25M of free cash flow in fiscal 2025.

How much operating cash flow does ZNTL produce?

Operating cash flow was -$125.25M, before capital expenditures of $0.00.